Efficacy of Dulaglutide (DU) as First Injectable Option for Patients with Type 2 Diabetes (T2D): A Post Hoc Pooled Analysis

被引：0
|
作者：
Patel, Hiren
Munir, Kashif M.
Sutherland, Sindee S.
Konig, Manige
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-2303-PUB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2303-PUB
引用
收藏
页数：2
相关论文
共 50 条
  • [11] TYPE 2 DIABETES PATIENTS SUBCLASSIFICATION ANALYSIS: PERSONALIZED T2D CARE OF DORZAGLIATIN
    Feng, L.
    Chen, C.
    Chen, L.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A87 - A87
  • [12] Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Once-Weekly Dulaglutide in Elderly Patients with Type 2 Diabetes (T2D)
    Loghin, Corina
    Schneck, Karen B.
    Cui, Xuewei
    Chien, Jenny Y.
    DIABETES, 2015, 64 : A259 - A259
  • [13] Reduction of HbA1c with dulaglutide in type 2 diabetes (T2D) patients negative, low positive or high positive for GAD antibodies (GADA): a post hoc analysis of AWARD-2,-4 and-5
    Pozzilli, P.
    Leslie, R. D.
    Peters, A.
    Buzzetti, R.
    Shankar, S. S.
    Milicevic, Z.
    Pavo, I.
    Lebrec, J.
    Martin, S.
    Schloot, N.
    DIABETOLOGIA, 2017, 60 : S68 - S68
  • [14] Changes in Lipid Concentrations in Patients with Type 2 Diabetes on Once-Weekly Dulaglutide 1.5 mg: Post-hoc Pooled Analysis of the AWARD Trials
    Sattar, Naveed A.
    Garcia-Perez, Luis E.
    Tao, Yebin
    Thieu, Vivian T.
    Pavo, Imre
    DIABETES, 2017, 66 : A288 - A289
  • [15] Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Moderate Renal Impairment
    Cherney, David
    Ferrannini, Ele
    Umpierrez, Guillermo E.
    Peters, Anne L.
    Rosenstock, Julio
    Carroll, Amy K.
    Sawhney, Sangeeta
    Banks, Phillip L.
    Jiang, Wenjun
    Lapuerta, Pablo
    DIABETES, 2020, 69
  • [16] Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Severe Renal Impairment
    Cherney, David
    Ferrannini, Ele
    Umpierrez, Guillermo E.
    Peters, Anne L.
    Rosenstock, Julio
    Carroll, Amy K.
    Lapuerta, Pablo
    Banks, Phillip L.
    Jiang, Wenjun
    Sawhney, Sangeeta
    DIABETES, 2020, 69
  • [17] Long-Term Tolerability of Saxagliptin as Add-On Therapy in Type 2 Diabetes (T2D): Pooled Analysis
    Allen, Elsie
    Fleming, Doug
    Berglind, Niklas
    Donovan, Mark
    Ohman, Peter
    DIABETES, 2011, 60 : A298 - A299
  • [18] Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV
    Pratley, Richard E.
    Dagogo-Jack, Samuel
    Charbonnel, Bernard
    Cherney, David
    Cosentino, Francesco
    Mcguire, Darren K.
    Essex, Margaret N.
    Jones, Philip L. S.
    Liu, Jie
    Adamsons, Ingrid A.
    Lawrence, David
    Shih, Weichung J.
    Cannon, Christopher P.
    DIABETES, 2021, 70
  • [19] Dulaglutide (DU) Has Better Glycemic Effectiveness vs. Basal Insulin (BI) in Injection-Naive Patients with Type 2 Diabetes (T2D): The DISPELTM Study
    Mody, Reema
    Huang, Qing
    Yu, Maria
    Zhang, Xian
    Wang, Liya
    Grabner, Michael
    Patel, Hiren
    DIABETES, 2019, 68
  • [20] Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies
    Kuang, Jian
    Zhu, Jiankun
    Liu, Siying
    Li, Quanmin
    DIABETES THERAPY, 2020, 11 (10) : 2329 - 2339
12345